Regeneus Ltd (ASX:RGS) Quarterly Results
Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 March, 2019.
Companies in the News
Biotech
Anatara Lifesciences Ltd (ASX:ANR) Morgans Financial Limited Interviews CEO Steven Lydeamore
While in Brisbane this week, Anatara Lifesciences CEO Steve Lydeamore (ASX:ANR) sat down with Scott Power, Senior Analyst at Morgans Financial Limited, Australia's largest national full-service retail stockbroking and wealth management network.
Anatara Lifesciences Ltd (ASX:ANR) Video Interview with CEO Steven Lydeamore on Development of Human Health Product
Anatara Lifesciences Ltd (ASX:ANR) CEO Steven Lydeamore, recently appointed to the company, is interviewed by ABN Newswire on the development of Irritable Bowl Syndrome (IBS) dietary supplements to address the growing need for a product that addresses the full range of IBS symptoms.
Anatara Lifesciences Ltd (ASX:ANR) PAC Partners Equity Research Report
PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.
Anatara Lifesciences Ltd (ASX:ANR) Pitt Street Research Report
Pitt Street Research has released its latest initiating research and valuation report on Anatara Lifesciences (ASX:ANR). The report provides a $1.34 per share base case and a $3.61 optimistic case using a probability-weighted DCF valuation approach.
Regeneus Ltd (ASX:RGS) Half-Year Report
Regeneus (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company developing a portfolio of novel cell-based therapies targeting significant unmet medical needs in human and animal health, with an initial focus on osteoarthritis, neuropathic pain and dermatology. The Company's product pipeline is underpinned by proprietary stem cell technologies.
Regeneus Ltd (ASX:RGS) Directors Provide $2.5M Loan to Extend Funding Runway
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that its Board of Directors have put in place loan funding of $2.5m to extend the Company's funding runway for the development and licensing of its clinical assets.
◂Previous Page
Biotech Next Page▸
Banking & Finance
- VIDEO: Lion Selection Group Ltd (ASX:LSX) CEO Hedley Widdup and Sean Russo Talk at the Australian Gold Conference 2024
- VIDEO: The Australian Gold Conference 2024 - Education Evening with Expert Panel
- Lithium Universe Ltd (ASX:LU7) Finalises Frankfurt and US OTC Listing
- ISX Financial Reports Strong Q2 2024 Results, Highlighting Robust Growth and Innovation
- NSX Limited (ASX:NSX) Company Update
- ASIC vs iSignthis Ltd and Nickolas John Karantzis
Oil Gas & Energy
- State Gas Limited (ASX:GAS) Advances Rolleston West
- Central Petroleum Limited (ASX:CTP) Operations and Activities Update
- Beetaloo Energy Australia Limited (ASX:BTL) Traditional Owners Consent to the Sale of Appraisal Gas
- Beetaloo Energy Australia Limited (ASX:BTL) Commences Carpentaria-5H Hydraulic Stimulation Operations
- Empire Energy Group Ltd (ASX:EEG) Change of Name and ASX Code
- VIDEO: Empire Energy Group Limited (ASX:EEG) Shareholder Support Erupts as Gas Production Draws Closer
Life Sciences
- Proteomics International Laboratories Ltd (ASX:PIQ) AMA Grants Reimbursement Code for Next-Gen PromarkerD Test
- Proteomics International Laboratories Ltd (ASX:PIQ) Funding Boost for Precision Diagnostics Proteomics Facility
- Proteomics International Laboratories Ltd (ASX:PIQ) First Patent for Endometriosis Blood Test - Granted in Japan
- Proteomics International Laboratories Ltd (ASX:PIQ) Next-gen PromarkerD test system released for predicting Diabetic Kidney Disease
- Proteomics International Laboratories Ltd (ASX:PIQ) PromarkerD Launched into the US at Major Diabetes Conference
- Proteomics International Laboratories Ltd (ASX:PIQ) A Landmark in Non-Invasive Esophageal Cancer Diagnosis
Social Media
